Home >> ALL ISSUES >> 2018 Issues >> Labs take stock of surprising flu season

Labs take stock of surprising flu season

Print Friendly, PDF & Email

Amy Carpenter Aquino

March 2018—In a severe flu season that started early, laboratories faced unprecedented test volumes, used new testing platforms, and negotiated vendor supply shortages.

When laboratory staff at Arkansas Children’s Hospital in Little Rock began seeing a rising number of requests for respiratory tests, and five positive flu results, in September 2017, they suspected they were in for a record flu season, says Sherry Childress, BSMT(ASCP), technical chief, molecular diagnostics and immunology.

Sherry Childress (left) and Dr. Gail Woods with Dr. José Romero at Arkansas Children’s. “I think everyone around the country has been surprised by the number of cases we’re seeing,” Dr. Romero says.

Sherry Childress (left) and Dr. Gail Woods with Dr. José Romero at Arkansas Children’s. “I think everyone around the country has been surprised by the number of cases we’re seeing,” Dr. Romero says.

By the end of January, the laboratory had performed triple the number of flu tests compared with the previous flu season. The percent of samples testing positive through the end of January, for nucleic acid amplification and direct antigen testing combined, was 27.2. For the same period in 2016–17, it was 3.3.

“I think everyone around the country has been surprised by the number of cases we’re seeing,” says José Romero, MD, director, pediatric infectious diseases section, Arkansas Children’s Hospital. “We’re doing approximately 300 percent more,” he says of the hospital’s test volume.

Gail L. Woods, MD, who recently retired as chief of pediatric pathology at the hospital, says the laboratory uses the BioFire FilmArray res­piratory panel throughout the year and the CLIA-waived Quidel Sofia Influenza A+B fluorescent immunoassay only during flu season.

“When you’re in season,” Dr. Romero says, “the risk of having a false-positive goes down, so we prefer to use the rapid antigen. Certainly, PCR has a place if the patient is in the intensive care unit or one of the heme-onc units. I think the doctors are using it appropriately in-house.”

The laboratory switches to rapid antigen testing for flu when the number of positive results by PCR rises by 10 percent, which Dr. Romero says usually occurs no earlier than late December.

“In the 2016–2017 season,” Childress says, “we started rapid testing in mid-January. This year, we started it in November.” The laboratory has had a 40 percent positivity rate on the rapid antigen tests alone from Dec. 1 to Jan. 31.

Despite the flu season’s early start, the laboratory felt prepared, Childress says, because staff had the resources needed to provide rapid flu and comprehensive respiratory testing. “What we weren’t prepared for was vendor supply stocks that weren’t able to meet demand for a period of time in December,” she says. “It made us change the way we do business here in PCR testing.”

When it ran short of kits, the laboratory triaged testing through the infectious disease department to preserve its stock of Bio­Fire Film­Array respiratory panels. Patients who needed primarily flu or respiratory syncytial virus testing had a rapid antigen test, while physicians were required to get authorization from an infectious disease physician to order PCR testing for patients who needed the comprehensive panel. “And we’re still doing that,” Dr. Romero says, “though we’re not adhering to it as strictly as we were before.”

BioFire resolved the assay shortage quickly, Childress says. “They worked very hard with us because we were a pediatric hospital and they wanted to make sure we had what we needed.”

FilmArray respiratory panel testing at Arkansas Children’s shows that rhinovirus/enterovirus represents the largest percentage of positive pathogens (31 percent) among patients so far this year, followed by RSV at 17 percent, Childress says. The laboratory has seen a significant number of coronavirus OC43 and adenovirus cases.

Among positive flu cases, the laboratory saw 78 percent flu A and 22 percent flu B, which is different from last year, which saw 97 percent flu A, Dr. Woods says. The percentages of rhinovirus, enterovirus, and RSV cases were about the same for both years.

For next year’s flu season, Dr. Romero, who is also the Horace C. Cabe endowed chair in infectious diseases, University of Arkansas for Medical Sciences, would like to see a plan for handling an assay reagent shortage for both the antigen test and PCR panel. Though the triaging of testing worked well this year, he says, “we got caught unaware and had to make things up on the fly.” Childress is looking forward to completing verifications on the laboratory’s additional Sofia analyzer and training staff on a new BioFire Torch for the FilmArray respiratory panels, with the goal of providing PCR test results around the clock.

“For the lab’s part, I think it’s been fabulous to have a good rapid assay and the option of performing a comprehensive PCR panel,” Childress says. “We are getting really good, quick turnaround times, accurate data, efficiently reported. That’s very important to have, especially in a pediatric hospital.”

Interesting in several ways” is how Kevin Homer, MD, describes the 2017–18 flu season at Texas Health Huguley Hospital in Fort Worth. This flu season began the first week of December, six to eight weeks earlier than usual for the area.

Dr. Homer

Dr. Homer

“It peaked the week between Christmas and New Year’s,” says Dr. Homer, who is chair of pathology and laboratory medical director at the hospital. “We ran more flu tests than we have ever run before in the history of our laboratory—over 450 flu tests that week.”

Of those 450 tests, 45 percent were positive for influenza or RSV. “Most of those positives were flu A,” Dr. Homer said in a Jan. 31 interview.

Dr. Homer, president of Huguley Pathology Consultants, has also noticed a slow but steady and significant rise in flu B since early December. “The first week of flu season, we had two [flu B] positive results, and last week we had 43.”

This flu season marks Huguley Hospital’s transition to rapid molecular PCR testing with the Cobas Liat system, a decision the laboratory and medical teams reached after two years of planning and conducting trials on several different platforms. “This is the only flu test we offer right now,” Dr. Homer says, adding that clinicians had grown frustrated with the unreliable results of the rapid antigen test used previously.

Satisfaction with flu test results is up substantially since the laboratory implemented the Liat on Nov. 30, 2017. “The ED doctors and the pulmonologists in primary care are saying, ‘We love this new test because the results match our clinical impression,’” Dr. Homer says. Microbiology specialists and laboratory generalists run the tests 24/7 and turn them around in about 30 minutes.

LabsTakeStock_Graph1Huguley Hospital is taking advantage of what Dr. Homer calls a “bonus” testing option of the Liat: the Cobas Influenza A/B and RSV assay.

“There was discussion about whether it was appropriate to test adults for RSV,” Dr. Homer says. “The pulmonologists especially thought that would be very helpful to them. It was their belief that RSV among adult patients with upper res­piratory symptoms had a higher incidence than had been recognized.”

Testing adults for RSV by a rapid method was not an option until this flu season because the in-house RSV test kit used previously had been validated only for patients age 20 and under. Implementing the Cobas Influenza A/B and RSV assay on all patients who present with flu-like illness has validated pulmonologists’ assumptions. “The incidence of RSV among adult patients is higher than we had recognized previously,” Dr. Homer says. “It’s a minority, obviously, of our positive tests, but it’s a significant number of patients.”

Armed with more precise information, clinicians have cut down on the spread of RSV within the hospital by isolating admitted patients who test positive, which has also reduced absenteeism among nurses and other staff, Dr. Homer says. “We didn’t know what it was in years past. They were just getting sick.”

But momentum in the fight against RSV hit a Texas-sized roadblock during the third week of January when the laboratory ran out of flu A/B plus RSV assays, and Dr. Homer was told new supplies were not immediately available.

“Unfortunately, Roche has not been able to keep up with the demand for these kits, and as of last week, we had to switch to the flu A/B and not offer the RSV,” Dr. Homer says. “The clinicians are not happy about that, but there’s nothing we can do until the supply is replenished.”

In the meantime, the laboratory is using the RSV test kit it formerly used for patients age 20 and under and sending out RSV tests for older patients as needed.

Roche apologized for the flu A/B plus RSV assay shortage but said it would be several weeks before the laboratory could expect a new shipment. “Probably when the flu season is over, to be honest,” Dr. Homer says.

In response to a CAP TODAY inquiry, Roche on Feb. 6 said it was experiencing unprecedented demand for its flu A/B plus RSV test for the Cobas Liat platform in a season in which cases of influenza-like illness have reached historic levels, second only to the 2009 pandemic. “We’re excited about the market adoption of our new point-of-care PCR technology, but the demand has created a temporary supply interruption for our flu A/B plus RSV assay. We expect to have it back in stock shortly,” said Nate Patton, director of marketing for the Cobas Liat system.

“They did not anticipate the demand for this test,” Dr. Homer says. “I think they anticipated that sites using their tests would implement both the flu A/B and the flu A/B plus RSV options, and the clinicians would only choose to add the RSV option on younger patients.” And that’s on top of the unusually heavy flu season.

Despite the temporary setback, the advantages of rapid molecular PCR testing are clear, even partway through the flu season. Positivity rates for flu A, flu B, and RSV were at 37 percent as of Feb. 1, compared with a 17 percent positivity rate using the rapid antigen test during the 2016–17 flu season.

“We’re certainly detecting more patients with disease, and it has a higher correlation, at least anecdotally, with what the clinicians are seeing,” Dr. Homer says.

“The point of this project was to demonstrate we could serve the ED with a rapid molecular flu test that they could rely on,” he says. Inventory issues notwithstanding, “I think we’ve done that. If we can get the inventory problems corrected for next flu season, I think we’ve moved the bar on testing.”

More than 100 nursing homes in northwest Louisiana, east Texas, and southern Arkansas rely on the testing services of Doctors Lab, an independent clinical laboratory in Shreveport. “We have never had a year before like this, ever,” says owner Donna Poimboeuf, BSMT(ASCP).

Since detecting the first positive flu results in early December, Poimboeuf and her staff have been using Meridian Bioscience’s Tru Flu kit to test specimens 24 hours daily. When laboratory staff run short of the Tru Flu kits, they supplement with another rapid antigen test, the BioSign Flu A and B from Germaine Laboratories.

Her clients’ need for rapid turnaround times has been so great, Poimboeuf says, that nursing home directors cannot wait for the phlebotomists’ regular, predawn appointments to collect specimens. “They want to know immediately so they can start quarantining and treating them,” she says of the residents. “The first time we tested, we were getting 19 or 20 people positive. In a nursing home, that’s really bad.”

One challenge has been keeping laboratory staff healthy. “I’ve had quite a few employees who have tested positive for flu,” Poimboeuf says. It required her to add staff and hours to the laboratory’s schedule, in addition to adding staff to night and weekend shifts to handle the unusual load. “We’re almost running a full shift after hours.”

Poimboeuf recommends that all phlebotomists practice universal precautions. “A lot of our phlebotomists used to laugh at the whole mask thing,” she says. “Well, they don’t laugh anymore.”

Although northern California has not seen quite the same level of flu activity as other areas of the country, the number of flu tests across the University of California Davis Health system doubled from December to January.

“We’re seeing the increase in the West Coast,” says Nam K. Tran, PhD, associate professor of clinical pathology and director of clinical chemistry, toxicology, and point-of-care testing at the UC Davis School of Medicine. “The CDC said flu season is peaking, but California can lag behind the East Coast.”

Laboratory staff reviewed flu data as far back as 2009 for comparison. “This isn’t as bad as the H1N1 from 2009, but this is obviously one of the more severe years with a predominantly—based on our molecular test results—H3N2 virus,” he says. He notes that different variants of the H1 virus are the next most commonly seen virus, with a rare instance of the H1N1 from 2009 detected.

Dr. Tran

Dr. Tran

Dr. Tran spoke with CAP TODAY one week after the UC Davis Medical Center went live with molecular point-of-care testing for flu in the ED with the CLIA-waived Cobas Influenza A/B assay on the Roche Cobas Liat system. “We actually did the transition just as the season began to get worse,” says Dr. Tran, who credits planning and teamwork for the smooth switch from rapid influenza diagnostic testing and administrators who heeded the lab’s warning that better technology was needed.

“I will quote our ED nurses since they bear the brunt of any testing during flu season,” Dr. Tran says: “‘We aren’t stressed out, or feel we are running low on supplies, or overwhelmed.’”

He reports a surplus of flu tests and judicious use of anti-influenza drugs in the ED: “We’ve been navigating it quite well.”

In addition to the Liat, UC Davis relies on the respiratory viral panels of GenMark Diagnostics and BioFire. RSV testing on the BioFire instrument is limited to ED patients as part of a quality project. “As recommended by guidelines, treatment for RSV is supportive care. If you’re a high-risk patient with RSV, you’re probably going to the emergency room in the first place, so you don’t need this test in the clinics,” Dr. Tran says.

“But for flu testing, if you only have a question of ‘Does this patient have the flu or not?’ and it is not necessary to differentiate between other pathogens such as rhinovirus, then by all means run the Liat,” he says. “It’s far more cost-effective and time-effective to run a 15- to 20-minute test at the point of care in the ED or clinics versus sending it to the clinical lab for the full respiratory panel, which could take a couple of hours for same-day results.”

One common exception is pediatric patients who exhibit symptoms that overlap with whooping cough. “We would recommend, especially for high-risk children, to do the [BioFire] panel, or similar platforms, because we can actually test for Bordetella pertussis using these devices,” Dr. Tran says.

The core laboratory’s commitment to switching to molecular testing for flu dates back to the 2009 H1N1 swine flu pandemic. “UC Davis was one of the few places that recognized back in 2009 that immunoassay tests were inadequate for swine flu detection,” Dr. Tran says.

Accuracy for the previously available tests varied widely, ranging from 10 to 70 percent, depending on the population, says Larissa May, MD, MSPH, MSHS, professor of emergency medicine and director of ED antibiotic stewardship at UC Davis School of Medicine. “Typically, for the patients for whom we were most needing to know the diagnosis, the test performed relatively poorly.”

That includes high-risk patients, for whom the CDC recommends antiviral treatment, even with a negative rapid antigen test result. “That made the test not very useful, and a lot of folks were either not diagnosing or not testing,” Dr. May says. “Now that we have this accurate test, we can use it in our high-risk patients to determine who needs treatment or whether high-risk household contacts should be considered for prophylaxis.”

Dr. May calls molecular POC testing a game changer for influenza diagnosis. “The sensitivity is pretty close to 100 percent for influenza, and the specificity is very good as well.”

The 20-minute test run time on the Cobas Liat is “not unreasonable” for a diagnostic test, she notes, even for patients being discharged from the ED.

When it came to training nearly 200 UC Davis Health emergency nurses to perform molecular flu tests, clinical nurse educator Jennifer Mattice, MS, RN, says she focused on consistency in training and cleanliness in test performance. “You have to be careful that you don’t contaminate the specimen and get a false-positive,” she says, adding that it was one of her “biggest teaching points.” By early February, nearly 90 percent of nurses were trained on one of the two Liats in the ED.

“The staff were excited to learn something new, and they respected that this was a better type of flu testing than what we had before,” Mattice says.

Aligning the Liat devices with the UC Davis antibiotic stewardship program is underway. “That’s starting as we speak and in parallel,” Dr. Tran says. “Stay tuned.”

Amy Carpenter Aquino is CAP TODAY senior editor.


Check Also

New contender speeds ID with susceptibility testing

May 2018—If a seismic shift were to happen in microbiology, the technology behind the Accelerate Pheno system and PhenoTest BC test kit, which won FDA approval last year as a rapid pathogen identification and antimicrobial susceptibility testing (AST) system for blood cultures, could well be the cause.